Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Gastrointestinal 2Thoracic 1Other hematologic neoplasm 1Myeloid 1CNS 1Breast 1

Conditions

Multiple Myeloma 2Recurrence 1

Interventions

Dexamethasone 140Lenalidomide 60Bortezomib 56Calcium Dobesilate 48Melphalan 44carfilzomib 40pomalidomide 39Cyclophosphamide 38daratumumab 27belantamab mafodotin 22ixazomib 19Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 16fludarabine 16dexamethasone acetate 14Bendamustine Hydrochloride 14Whole-Body Irradiation 13Filgrastim 13dexamethasone 21-phosphate 12Tacrolimus 12venetoclax 11auricularum 11Prednisone 11selinexor 10liposomal doxorubicin 10iberdomide 10Mycophenolic Acid 10isatuximab 9Cyclosporine 9pembrolizumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × TIC10 compound × Plasma cell × Clear all
NCT02863991 2024-07-03

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Jazz Pharmaceuticals

Phase 1/2 Terminated
17 enrolled 10 charts
Plasma cell

Multiple Myeloma

NCT03492138 2020-05-29

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Icahn School of Medicine at Mount Sinai

Phase 1/2 Terminated
5 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡